Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or by killing them. It also prepares the patient's bone marrow for the stem cell transplant. The stem cells are given to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving isotretinoin after transplant may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given before a stem cell transplant and isotretinoin in treating neuroblastoma.

PURPOSE: This randomized clinical trial is studying two different combination chemotherapy regimens to compare how well they work when given before a stem cell transplant and isotretinoin in treating young patients with high-risk neuroblastoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
• Treatments: 3-Iodobenzylguanidine; Carboplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Etoposide phosphate; Ifosfamide; Isotretinoin; Liposomal doxorubicin; Melphalan; Topotecan; Vincristine; Vindesine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of neuroblastoma according to any of the following criteria:

• Histological diagnosis from tumor tissue

• Presence of distinct neuroblastoma cells in the bone marrow and elevated catecholamine metabolites (HVA, VMA) in blood or urine

• High-risk disease, meeting 1 of the following criteria:

• Stage 4 disease, regardless of the MYCN status (1-21 years of age)

• Stage 1-3 or 4S disease with MYCN amplification (6 months -21 years of age)

PATIENT CHARACTERISTICS:

• Not pregnant or nursing

• Fertile patients must use effective contraception (hormonal contraception or intra-uterine device [IUD])

PRIOR CONCURRENT THERAPY:

• No concurrent participation in another clinical trial that would preclude the interventions or outcome assessment of this clinical trial

• No other concurrent anticancer therapy